A severe epidemic of serogroup A meningococcus meningitis occurred in the northwest Central African Republic from January to March 1992. Strains from 24 patients were characterized using serotyping, testing of susceptibility to antibiotics, and multilocus enzyme electrophoresis. In 23 of the 24 patients the causal strain was found to be 4:P1.9/clone III-1. These results indicate that such strains continue to spread in Africa and have taken hold in areas outside the "meningitis belt." This may be a consequence of changing climatic conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF01982194DOI Listing

Publication Analysis

Top Keywords

central african
8
african republic
8
characteristics serogroup
4
serogroup neisseria
4
neisseria meningitidis
4
meningitidis strains
4
strains isolated
4
isolated central
4
republic february
4
february 1992
4

Similar Publications

Background: Nevus of Hori (HN) has been primarily reported in patients of Eastern Asian descent, with a paucity of data regarding HN occurring in African patients. In this study, we report on South African patients with HN initially thought to have melasma.

Objective: To characterize the histopathological and clinical phenotypes of HN in African patients.

View Article and Find Full Text PDF

First Report of Causing Collar Rot of gilo in Ghana.

Plant Dis

January 2025

University of Ghana College of Basic and Applied Sciences, Biotechnology Centre, Accra, Greater Accra, Ghana;

African eggplant (Solanum aethiopicum gilo group) is a nutritious vegetable widely commercialized in Ghana. In the 2021 planting season (May-July), collar rot symptoms were observed on African eggplant on a farm at Domeabra, Legon, and Okumaning in the Central (N5° 48' 11″, W1° 26' 48″), Greater Accra (N5° 39' 34″, W0° 11' 34″) and Eastern (N6° 8' 34″, W0° 55' 59″) regions of Ghana, respectively. Disease incidence was 8-15% in the different farms.

View Article and Find Full Text PDF

Toxoplasma gondii from Gabonese forest, Central Africa: First report of an African wild strain.

PLoS Negl Trop Dis

January 2025

Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France.

The protozoan Toxoplasma gondii is a ubiquitous and highly prevalent parasite that can theoretically infect all warm-blooded vertebrates. In humans, toxoplasmosis causes infections in both immunodeficient and immunocompetent patients, congenital toxoplasmosis, and ocular lesions. These manifestations have different degrees of severity.

View Article and Find Full Text PDF

Sarcoidosis is a multisystem disease process with a bimodal distribution typically affecting African American women and those of Scandinavian descent characterized by noncaseating granulomatous disease. We present a case of a 29-year-old African American male patient who was seen in the clinic for recurrent symptomatic cholelithiasis. He had no past medical history or symptoms besides intermittent postprandial right upper quadrant (RUQ) pain with imaging confirming cholelithiasis.

View Article and Find Full Text PDF

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Lancet Respir Med

December 2024

Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:

Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 6-11 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!